Institute of Neuroscience,Newcastle University,Newcastle upon Tyne and Regional Affective Disorders Service,Northumberland Tyne and Wear NHS Foundation Trust,Newcastle upon Tyne.
Advanced Interventions Service,Ninewells Hospital & Medical School,Dundee.
Br J Psychiatry. 2018 May;212(5):274-278. doi: 10.1192/bjp.2017.33.
Many novel therapeutic options for depression exist that are either not mentioned in clinical guidelines or recommended only for use in highly specialist services. The challenge faced by clinicians is when it might be appropriate to consider such 'non-standard' interventions. This analysis proposes a framework to aid this decision.Declaration of interestIn the past 3 years R.H.M.W. has received support for research, expenses to attend conferences and fees for lecturing and consultancy work (including attending advisory boards) from various pharmaceutical companies including Astra Zeneca, Cyberonics, Eli Lilly, Janssen, LivaNova, Lundbeck, MyTomorrows, Otsuka, Pfizer, Roche, Servier, SPIMACO and Sunovion. D.M.B.C. has received fees from LivaNova for attending an advisory board. In the past 3 years A.J.C. has received fees for lecturing from Astra Zeneca and Lundbeck; fees for consulting from LivaNova, Janssen and Allergan; and research grant support from Lundbeck.In the past 3 years A.C. has received fees for lecturing from pharmaceutical companies namely Lundbeck and Sunovion. In the past 3 years A.L.M. has received support for attending seminars and fees for consultancy work (including advisory board) from Medtronic Inc and LivaNova. R.M. holds joint research grants with a number of digital companies that investigate devices for depression including Alpha-stim, Big White Wall, P1vital, Intel, Johnson and Johnson and Lundbeck through his mindTech and CLAHRC EM roles. M.S. is an associate at Blueriver Consulting providing intelligence to NHS organisations, pharmaceutical and devices companies. He has received honoraria for presentations and advisory boards with Lundbeck, Eli Lilly, URGO, AstraZeneca, Phillips and Sanofi and holds shares in Johnson and Johnson. In the past 3 years P.R.A.S. has received support for research, expenses to attend conferences and fees for lecturing and consultancy work (including attending an advisory board) from life sciences companies including Corcept Therapeutics, Indivior and LivaNova. In the past 3 years P.S.T. has received consultancy fees as an advisory board member from the following companies: Galen Limited, Sunovion Pharmaceuticals Europe Ltd, myTomorrows and LivaNova. A.H.Y. has undertaken paid lectures and advisory boards for all major pharmaceutical companies with drugs used in affective and related disorders and LivaNova. He has received funding for investigator initiated studies from AstraZeneca, Eli Lilly, Lundbeck and Wyeth.
许多新型治疗抑郁症的方法都存在，这些方法要么在临床指南中没有提到，要么只推荐在高度专业化的服务中使用。临床医生面临的挑战是，何时考虑这种“非标准”干预措施才是合适的。本分析提出了一个框架来帮助做出这个决策。
利益声明
在过去 3 年中，R.H.M.W. 从各种制药公司获得了研究支持、参加会议的费用以及演讲和咨询工作（包括参加顾问委员会）的费用，这些公司包括阿斯利康、Cyberonics、礼来、杨森、LivaNova、Lundbeck、MyTomorrows、大冢、辉瑞、罗氏、Servier、SPIMACO 和 Sunovion。D.M.B.C. 因参加顾问委员会而从 LivaNova 获得报酬。在过去 3 年中，A.J.C. 因在阿斯利康和 Lundbeck 演讲而获得报酬；因在 LivaNova、杨森和 Allergan 咨询而获得报酬；并因 Lundbeck 的研究资助而获得报酬。在过去 3 年中，A.C. 因在 Lundbeck 和 Sunovion 演讲而获得报酬。在过去 3 年中，A.L.M. 通过他的 mindTech 和 CLAHRC EM 角色获得了参加研讨会和咨询工作（包括顾问委员会）的费用，这些费用来自 Medtronic Inc 和 LivaNova。R.M. 与许多研究用于治疗抑郁症的设备的数字公司（包括 Alpha-stim、Big White Wall、P1vital、Intel、Johnson and Johnson 和 Lundbeck）共同拥有研究资助，通过他的 mindTech 和 CLAHRC EM 角色。M.S. 是 Blueriver Consulting 的一名顾问，为 NHS 组织、制药和设备公司提供情报。他因在 Lundbeck、礼来、URGO、阿斯利康、飞利浦和赛诺菲的演讲和顾问委员会而获得酬金，并持有 Johnson and Johnson 的股份。在过去 3 年中，P.R.A.S. 从生命科学公司获得了研究支持、参加会议的费用以及演讲和咨询工作（包括参加顾问委员会）的费用，这些公司包括 Corcept Therapeutics、Indivior 和 LivaNova。在过去 3 年中，P.S.T. 作为顾问委员会成员从以下公司获得了咨询费：Galen Limited、Sunovion Pharmaceuticals Europe Ltd、myTomorrows 和 LivaNova。A.H.Y. 为所有主要制药公司（包括用于治疗情感和相关障碍的药物）和 LivaNova 进行了付费演讲和顾问委员会工作。他还从阿斯利康、礼来、Lundbeck 和惠氏获得了用于研究者发起的研究的资金。
